Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Microbot Medical Inc. is a medical device company focused on the research, development, and commercialization of innovative robotic technologies for minimally invasive endovascular and surgical procedures. The company operates within the medical devices and robotic-assisted surgery industries, with a strategic emphasis on improving precision, safety, and efficiency in catheter-based interventions.
The company’s primary value proposition is its development of next-generation robotic platforms designed to eliminate the need for manual catheter manipulation and reduce physician exposure to radiation. Microbot Medical does not currently generate significant commercial revenue and is primarily driven by research and development activities. Founded in 2010 and originally established through the merger of U.S.- and Israel-based medical technology assets, the company has evolved into a development-stage organization publicly listed on Nasdaq under the ticker MBOT.
Business Operations
Microbot Medical’s operations center on the development of its proprietary LIBERTY® Endovascular Robotic System, which is designed to remotely control off-the-shelf guidewires and catheters during endovascular procedures. The system is intended to be compact, bedside-mounted, and compatible with existing cath lab workflows, differentiating it from larger, capital-intensive robotic systems.
The company conducts research and development activities primarily in Israel, while maintaining corporate, regulatory, and capital markets functions in the United States. Microbot Medical does not currently report commercialized products or recurring service revenue, and its operating expenses are largely attributable to engineering development, preclinical and clinical testing, intellectual property protection, and regulatory preparation. As of the latest public disclosures, the company does not report material joint ventures or revenue-generating subsidiaries.
Strategic Position & Investments
Microbot Medical’s strategic direction is focused on advancing the LIBERTY® Endovascular Robotic System toward regulatory clearance, particularly in the United States, with the goal of entering the global endovascular robotics market. The company’s growth strategy emphasizes regulatory milestones, system validation, and eventual commercialization through potential distribution partnerships rather than large-scale direct sales infrastructure.
The company has historically grown through internal development rather than acquisitions and has not disclosed significant acquisitions or equity investments in external portfolio companies. Its technological focus aligns with broader trends in robotic-assisted minimally invasive surgery, interventional cardiology, and vascular procedures, particularly where physician radiation exposure and procedural precision are critical concerns.
Geographic Footprint
Microbot Medical maintains a bi-national operational footprint, with corporate headquarters and executive management based in the United States and primary research and development activities conducted in Israel. This structure reflects the company’s access to Israel’s medical device engineering ecosystem while remaining integrated into U.S. capital markets and regulatory frameworks.
The company does not currently operate manufacturing facilities or commercial sales organizations in other regions and has limited direct market presence outside North America and the Middle East. Its future geographic expansion is expected to be driven by regulatory approvals and commercialization efforts in North America, Europe, and other major medical device markets.
Leadership & Governance
Microbot Medical is led by executives with experience in medical devices, healthcare technology, and public company management. The leadership team emphasizes capital efficiency, disciplined product development, and a focused regulatory strategy as core elements of its governance and operating philosophy.
Key executives include:
- Harel Gadot – Chairman of the Board, Chief Executive Officer, and President
- Seth H. Hastings – Vice President of Finance
- Tehila Ben Moshe – Vice President of Research and Development
The company is governed by a board of directors responsible for oversight of strategy, risk management, and shareholder interests, consistent with U.S. public company governance standards.